KORU Medical Systems (NASDAQ:KRMD) Stock Price Expected to Rise, Piper Sandler Analyst Says

KORU Medical Systems (NASDAQ:KRMD) had its price target lifted by Piper Sandler from $3.00 to $3.50 in a research report sent to investors on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Separately, B. Riley assumed coverage on shares of KORU Medical Systems in a research note on Thursday, July 25th. They issued a “buy” rating and a $4.00 price objective for the company.

KORU Medical Systems Price Performance

KRMD opened at $3.17 on Thursday. KORU Medical Systems has a 1 year low of $1.98 and a 1 year high of $3.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.99 and a quick ratio of 3.27. The company has a market capitalization of $145.31 million, a price-to-earnings ratio of -12.68 and a beta of 0.41. The firm’s fifty day moving average price is $2.67 and its two-hundred day moving average price is $2.48.

Institutional Investors Weigh In On KORU Medical Systems

Several institutional investors have recently added to or reduced their stakes in the business. Aaron Wealth Advisors LLC bought a new stake in shares of KORU Medical Systems in the second quarter valued at approximately $28,000. Allspring Global Investments Holdings LLC bought a new stake in KORU Medical Systems during the 2nd quarter valued at $28,000. XTX Topco Ltd purchased a new stake in shares of KORU Medical Systems during the third quarter worth $34,000. Legato Capital Management LLC bought a new position in shares of KORU Medical Systems in the second quarter worth $35,000. Finally, Virtu Financial LLC bought a new position in shares of KORU Medical Systems in the first quarter worth $63,000. 58.60% of the stock is owned by hedge funds and other institutional investors.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.